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Summary Of 221 patients with breast cancer of known epidermal growth factor receptor (EGFR) and
oestrogen receptor (ER) status, 99 had developed recurrences during the period of follow-up (range 3-60
months, median 24 months). Of these, 72 received endocrine therapy as first-line treatment for relapse.
Immunohistochemical assessment of c-erbB-2 protein product expression was made using paraffin-embedded
tumour tissue from 65 of these 72 patients. Including patients whose disease remained stable for more than 6
months with those showing an objective response (CR or PR for more than 3 months), only one (7%) of 14
c-erbB-2 positive tumours responded to endocrine manipulation compared with 19 (37%) of 51 c-erbB-2
negative tumours (P<0.05). Coexpression of c-erbB-2 reduced the response rate of ER positive patients from
48% to 20% and of ER negative cases from 27% to 0% (P<0.01). EGFR and c-erbB-2 protein appeared to
have additive effects in reducing the likelihood of response, and none of eight patients with EGFR positive,
c-erbB-2 positive tumours derived benefit from endocrine therapy. The results of this study suggest that
c-erbB-2 protein overexpression, a marker of poor prognosis in breast cancer, is associated with a lack of
response to endocrine therapy on relapse, and particularly in combination with EGFR may be useful in
directing therapeutic choices.
In breast cancer, expression of oestrogen receptor (ER) by
the primary tumour is associated with an increased likelihood
of response to endocrine therapy in those with advanced
disease (De Sombre et al., 1979; Jansen, 1981; Hawkins,
1985). However, up to 50% of patients with receptor positive
tumours will not benefit from such therapy, while approx-
imately 10% of receptor negative tumours respond, and early
identification of patients with tumours falling into the latter
two groups would allow their allocation to other modes of
treatment. Furthermore, there is evidence that patients with
early disease who derive benefit from tamoxifen do so
irrespective of their ER status (Nolvadex Adjuvant Trial
Organisation, 1985; Breast Cancer Trials Committee, 1987)
and some have questioned whether routine assessment of
steroid receptor status is of value in the management of
patients with breast cancer (Barnes et al., 1988).
There is thus a need to identify parameters providing a
more precise indication of the response to endocrine therapy.
Moreover, increased understanding of the mechanisms of
hormone resistance may allow development of new thera-
peutic approaches. Recent evidence suggests that overexpres-
sion of the protein product of the c-erbB-2 oncogene is an
indicator of poor prognosis in breast cancer (Perren, 1991).
We have examined a series of 221 patients of known ER and
EGFR status to investigate the effect of c-erbB-2 oncoprotein
overexpression on response to endocrine therapy.
Patients and methods
Tumour tissue from 221 patients with primary operable
breast cancer was collected over a 60 month period. No
adjuvant systemic chemotherapy or hormonal therapy was
given to these patients. The median follow-up time was 24
months (range 3-60 months). On relapse, postmenopausal
patients received tamoxifen (20 mg daily) as first-line therapy
and low-dose aminoglutethimide (125 mg twice daily) and
hydrocortisone (20 mg twice daily) as second-line treatment.
Premenopausal patients underwent surgical or radiothera-
peutic ovarian ablation; second-line therapy was tamoxifen.
Objective (complete or partial) response to endocrine therapy
was assessed using UICC criteria (Hayward et al., 1977);
the minimum objective response duration accepted was 3
months. Patients were considered to have stable disease if
there was no change for 6 months. It has been demonstrated
that, in advanced breast cancer, patients with stable disease
have a similar survival to those showing a partial response
(Manni et al., 1979; Harris et al., 1983).
Expression of c-erbB-2 oncoprotein was assessed in sec-
tions of formalin-fixed, paraffin-embedded tumour tissue
using a streptavidin-biotin immunohistochemical technique as
previously described (Wright et al., 1989). The primary, poly-
clonal antibody had been raised against a synthetic peptide
(21N) representing residues 1243 to 1255 of the predicted
oncoprotein sequence, and immunoprecipitates a 190 kDa
protein from human cells (Gullick et al., 1987). Immunohis-
tochemical staining using this antibody correlates with
c-erbB-2 gene amplification (Gusterson et al., 1988) and is
abolished by preincubation with the immunising peptide.
Tumours showing intense membrane staining of 50% or
more tumour cells were regarded as positive and all others as
negative; in a previous study (Wright et al., 1989) application
of these criteria allowed stratification of patients into two
groups of differing prognosis. Levels of EGFR and ER were
determined using radioligand binding assays (Nicholson et
al., 1988; Crawford, 1984), with cut-off points of 10 fmol-
mg-' membrane protein for EGFR and 5 fmol mg-I cyto-
solic protein for ER.
Relationships between variables were examined by the chi-
squared test or Fisher's exact test, where appropriate. Sur-
vival curves were prepared by the life table method, with
comparisons between curves by the logrank test (Peto et al.,
1977).
Results
Response to tamoxifen
Of the 221 patients in the study, 99 had a recurrence within
the period of follow-up. Five patients died before treatment
was given, six received synchronous radiotherapy, nine were
Correspondence: C. Wright, Department of Histopathology, Royal
Victoria Infirmary, Newcastle upon Tyne NEI 4LP, UK.
Received 31 July 1991; and in revised form 19 September 1991.
'PI Macmillan Press Ltd., 1992 Br. J. Cancer (1992), 65, 118-121c-erbB-2 EXPRESSION AND RESPONSE TO ENDOCRINE THERAPY 119
given local therapy alone, and seven underwent chemother-
apy alone. Response to endocrine therapy could be deter-
mined for the remaining 72 patients (median age 56 years,
range 32-77 years), of whom 20 (28%) responded (14 partial
or complete responses, six with stable disease) and 52 (72%)
did not. The responder and non-responder groups did not
significantly differ with respect to age, menopausal status,
lymph node status, tumour size, type of breast surgery or site
of first relapse (Table I). Patients with low or intermediate
grade tumours, however, were more likely to respond than
those with high grade tumours (P = 0.024).
Response stratified by c-erbB-2 status
Tissue for immunohistochemistry was available from 65 of
the 72 patients, including all 20 responders. The seven
patients for whom sections were not available did not differ
markedly from those studied, with respect to clinical, marker
or response data. Of the 14 cases which were scored positive
for c-erbB-2 oncoprotein expression, only one (7%) showed a
response to endocrine therapy compared with 19 (37%) of
the 51 c-erbB-2 negative tumours (P<0.05, Fisher's exact
test). There was an apparent trend towards a shorter time
from relapse to disease progression for patients with c-erbB-2
positive tumours (Figure 1).
Interaction ofER and c-erbB-2 status
Thirty of the 65 tumours were ER positive and 35 ER
negative; those that were ER positive showed a greater
likelihood of response (43% vs 20%) although this asso-
ciation did not achieve statistical significance (X2 3.11,
P = 0.078). Patients with ER negative tumours showed more
rapid disease progression on endocrine therapy than those
with ER positive tumours (Figure 2). Coexpresson of c-erbB-
2 oncoprotein reduced the response rate of ER positive cases
from 48% to 20%, and of ER negative cases from 27%
down to 0% (Table II, P<0.01). Coexpression of EGFR
also reduced the response rate in ER positive and ER
negative tumours (Nicholson et al., 1989), and these data are
shown for comparison in Table II.
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Figure 1 Time to progression for patients receiving endocrine
therapy, stratified by c-erbB-2 status (as demonstrated by anti-
body 21N).
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Figure 2 Time to progression for patients receiving endocrine
therapy, stratified by ER status.
Interaction ofc-erbB-2 and EGFR status
Tumours expressing either c-erbB-2 or EGFR were less likely
to respond than those negative for both, while none of eight
c-erbB-2 positive, EGFR positive tumours were responders
(Table III, P<0.005), suggesting that the effects of the two
receptors are additive. Twenty of the 30 ER positive tumours
were negative for both c-erbB-2 and EGFR, and within this
double-negative group were equally distributed between res-
ponders and non-responders (Table III).
Table I Clinical data related to response to endocrine therapy.
No
response Response
Age <50 9 8 NS
>50 36 12
Operation Lumpectomy 5 5 NS
Mastectomy 40 15
Nodes - 19 13 NS
+ 26 7
Histological
Grade I 1 4 x2 = 7.41
(Bloom and II 12 7 P= 0.024
Richardson) III 29 8
Size T, (. 2cm) 6 4
T2(>2cm, k5cm) 31 15 NS
T3 (>Scm) 9 0
Relapse Soft tissue 18 9 NS
Skeletal 16 8
Visceral 11 3
NS = not significant.
Table II Response to endocrine therapy related to ER status and
stratified by growth factor receptor status
No response Response
c-erbB-2- ER + 13 (52%) 12 (48%)
(EGFR- ER + ) (12) (11)
c-erbB-2 + ER + 4 (80%) 1 (20%)
(EGFR + ER + ) (5) (2)
c-erbB-2 - ER - 19 (73%) 7 (27%)
(EGFR- ER-) (7) (4)
c-erbB-2 + ER - 9 (100%) 0 (0%)
(EGFR + ER-) (21) (3)
Chi-square for linear trend (c-erbB-2) = 6.87, 1 df, P<0.01.
(Chi-square for linear trend (EGFR) = 6.40, 1 df, P<0.05).
Discussion
The fact that many patients with ER positive breast cancers
fail to benefit from endocrine manipulation has been at-
tributed to the presence of non-functional receptors, and this
has stimulated a search for oestrogen-dependent proteins
which might potentially serve as more precise predictors of
hormone sensitivity. PgR is one such protein, and indeed
there is evidence that response rates are highest for tumours
containing both ER and PgR (de Sombre et al., 1979; Haw-
kins, 1985; Osborne et al., 1980). However, studies correl-
ating tumour levels of other oestrogen-regulated or -related
proteins, such as ER-D5 related antigen and P24, with ER120 C. WRIGHT et al.
Table III Response to endocrine therapy related to growth factor
receptor status
No response Response
c-erbB-2 - EGFR - 14 (10) 14 (10)
c-erbB-2 - EGFR + 18 (3) 5 2)
c-erbB-2 + EGFR - 5 (2) 1 (1)
c-erbB-2 + EGFR + 8 (2) 0 (0)
Chi-square for linear trend = 8.01, 1 df, P<0.005. (Number of ER
positive tumours in each subgroup shown in brackets).
status and response to endocrine therapy have to date pro-
duced conflicting results (Adams & McGuire, 1985; Cano et
al., 1986; Giri et al., 1987; Hawkins et al., 1987; Home et al.,
1988), prompting investigation of other possible predictors of
response.
There is considerable current interest in the role of growth
factors and their receptors in the development and progres-
sion of breast cancer. Expression of EGFR (the protein
product of the c-erbB-1 oncogene) is associated with poorer
prognosis (Sainsbury et al., 1987; Lewis et al., 1990). The
oncogene c-erbB-2 encodes a transmembrane protein with a
structure similar to, but distinct from, EGFR; two candidate
ligands have recently been described (Lippman & Lupu,
1991). Amplification and overexpression of c-erbB-2 is also
an independent indicator of early relapse and shorter overall
survival (Perren, 1991). In the current study, patients with
tumours showing overexpression of the c-erbB-2 oncoprotein
(assessed immunohistochemically) were considerably less like-
ly to benefit from endocrine therapy than those with c-erbB-2
negative tumours: only one of 14 c-erbB-2 positive tumours
showed evidence of response. For ER positive tumours, co-
expression of c-erbB-2 reduced the probability of response
from 48% to 20%, and none of nine ER negative, c-erbB-2
positive tumours responded. Thus, assessment of c-erbB-2
status appears to provide useful additional information with
regard to prediction of response on relapse. These data are in
keeping with the results of in vitro studies in which transfec-
ting MCF 7 breast cancer cells with c-erbB-2 conferred resis-
tance to tamoxifen (Benz et al., 1991).
Previously, we have reported that for the same group of
patients EGFR status was at least as good an indicator of
overall response as ER status, EGFR positivity being assoc-
iated, like c-erbB-2 overexpression, with a reduced likelihood
of response (Nicholson et al., 1989). In the present study,
none of eight EGFR positive, c-erbB-2 positive tumours
appeared to benefit from tamoxifen therapy. Furthermore,
there is evidence that these two parameters exert an additive
effect on survival, patients with double-positive tumours hav-
ing a particularly poor prognosis (Wright et al., 1989). It is
likely that the growth of breast tumours which overexpress
EGFR and/or c-erbB-2 protein is not controlled in the same
way as those which express steroid receptors. Growth factors
secreted by tumour or other (e.g. stromal) cells might over-
ride any effect of anti-oestrogens on tumour cell prolifera-
tion. However, even in the group showing expression of
neither c-erbB-2 nor EGFR, some patients with ER positive
tumours still failed to respond to hormone therapy (Table
III). Thus, there are probably multiple mechanisms involved
in hormone resistance in ER positive patients, which in
addition to c-erbB-1 (EGFR) and c-erbB-2 might include as
yet undiscovered oncogenes relating to growth factors and
their receptors. It is likely that the inclusion of growth factor
receptor status and expression of other oncogene products in
the biological profiles of breast tumours will improve our
ability to predict prognosis and allow us more accurately to
tailor modes of treatment for individual patients.
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